Phibro Animal Health (NASDAQ:PAHC) Research Coverage Started at Citigroup

Citigroup started coverage on shares of Phibro Animal Health (NASDAQ:PAHC) in a research report report published on Wednesday, MarketBeat reports. The brokerage issued a hold rating and a $62.00 price target on the stock.

A number of other analysts have also recently weighed in on the company. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research report on Friday, February 6th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and a consensus price target of $42.40.

Phibro Animal Health Trading Up 5.9%

NASDAQ PAHC opened at $57.07 on Wednesday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health has a one year low of $16.16 and a one year high of $60.08. The company has a 50-day simple moving average of $53.37 and a 200-day simple moving average of $45.08. The firm has a market capitalization of $2.31 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 0.83 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.8%. Phibro Animal Health’s payout ratio is currently 21.33%.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 110,842 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96. Following the sale, the chief executive officer directly owned 122,958 shares in the company, valued at $5,948,708.04. This trade represents a 47.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders sold 316,205 shares of company stock valued at $15,487,684. Corporate insiders own 50.13% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. 1620 Investment Advisors Inc. lifted its holdings in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC grew its position in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares in the last quarter. Rothschild Investment LLC increased its stake in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after buying an additional 1,000 shares during the period. Hughes Financial Services LLC acquired a new position in Phibro Animal Health during the 3rd quarter valued at about $40,000. Finally, iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $61,000. Institutional investors own 99.34% of the company’s stock.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Recent quarterly results and FY‑2026 guidance support the rally — Phibro beat EPS and revenue expectations and set FY‑2026 EPS guidance of roughly 2.93–3.10, helping justify the higher share price. MarketBeat PAHC coverage
• Positive Sentiment: Upgrades and positive analyst notes (e.g., Zacks upgrade to Strong Buy and reaffirmations from boutique shops) have increased investor interest and buying pressure. Analyst coverage summary
• Neutral Sentiment: Citigroup initiated coverage with a “neutral”/hold rating and a $62 price target (roughly single‑digit upside vs. current levels). That provides formal coverage but not a buy endorsement. Citigroup initiation
• Neutral Sentiment: Media discussion about whether it’s “too late” after a ~234.5% rally is drawing attention — this can attract momentum traders but also encourages re‑rating/valuation debate among longer‑term investors. Yahoo Finance article
• Negative Sentiment: CEO Jack Bendheim has sold multiple blocks of shares recently (most recently 7,040 shares at ~$54.64 on Apr 16). While the trades were executed under a pre‑arranged Rule 10b5‑1 plan (which limits informational inference), repeated insider sales can create short‑term caution among investors. InsiderTrades report

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.